3D MEDICINES

3D Medication Inc. (www.3d-medicines.com) is a pharmaceutical company focusing on the field of cancer treatment that has entered the commercialization stage. Adhering to the vision of “helping cancer patients live longer and better”, combined with the future trend of chronic cancer treatment, it develops next-generation oncology drugs for cancer patients around the world. The company's product line includes 12 innovative drug candidates with clinical value and differentiated or global leadership. Of these, 8 have entered clinical development or commercialization, including the world's first new PD-L1 monomonial antibody drug, which has been conditionally approved by the China Drug Administration to be marketed in China; the introduction of the first-in-class polypeptide tumor vaccine 3D189 and the Gas6/AXL inhibitor 3D229 has been approved by the FDA for global phase III MRCT clinical research; the self-developed multi-target kinase inhibitor 3D011 has also entered clinical trials In the development phase, the other 4 products targeting FGFR123\ EP4\ COX2\ CD47 respectively have also entered the clinical stage at home and abroad. Preclinical varieties also include the internationally leading dual antibody CD3xPD-L1. The company currently has an international team of more than 250 people in the development, production and commercialization of new drugs to explore better treatments for cancer patients around the world.